Fig. 6.
Kinase inhibitors reduce IMI amplitude. A: proctolin-induced IMI in different concentrations of KN-93. For statistical analysis, KN-93 was grouped into “low-dose” (2–5 μM range, average concentration 4.2 μM), and “high-dose” groups (10–20 μM range, average concentration 15 μM). A 1-way repeated-measures ANOVA showed that KN-93 significantly decreased proctolin-induced IMI amplitude at −15 mV [KN-93: F(2,5) = 34.09, P = 0.001]. B: proctolin-induced IMI at different concentrations of the MLCK inhibitor ML-7. A 1-way repeated-measures ANOVA showed that ML-7 decreased proctolin-induced IMI amplitude at −15 mV [ML-7: F(3,26) = 4.468, P = 0.012]. Post hoc Tukey test: *P < 0.05; **P < 0.01; ns, not significant. Error bars are SE.